HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Canada Proposes Tiered Risk Framework For Regulating Self-Care Items

This article was originally published in The Rose Sheet

Executive Summary

Marketers of traditional medicines and homeopathic products could have a harder time using health claims under Health Canada’s proposal for regulating “self-care” products. At the same time, the revised framework would grease the path to market for some dietary supplements and OTC drugs, while cosmetics requirements would be largely unaffected.

You may also be interested in...



Canada Tilts At Unneeded Fixes In Self-Care Product Regulation Overhaul – Industry

Health Canada says its planned overhaul will not scrap the current natural health product framework, but industry is skeptical. In a Council for Responsible Nutrition webinar, an industry consultant says marketers of OTC drugs, supplements and cosmetics are discussing the proposal's negative implications with the agency.

Roche Continues To Make The Case For Gantenerumab In Alzheimer’s Disease

The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.

Brinavess' US Review: EU Postmarket Data Unlikely To Save Troubled AFib Drug

Correvio's atrial fibrillation drug Brinavess will return to a US FDA advisory committee more than a decade after the agency first declined to approve the drug;  FDA still has a series of cardiovascular safety concerns related to the drug and is not convinced by data from the European experience.

Topics

UsernamePublicRestriction

Register

RS108549

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel